Anti-malarial drug shows promise in treating Covid-19
Japanese scientists suggest mefloquine culd be used to fight Covid-19
![Scientists modelled the effectiveness of mefloquine to predict its potential use if applied to treat covid-19](https://static.independent.co.uk/2020/10/22/23/AFP_8TN364.jpg)
Support truly
independent journalism
Our mission is to deliver unbiased, fact-based reporting that holds power to account and exposes the truth.
Whether $5 or $50, every contribution counts.
Support us to deliver journalism without an agenda.
![Louise Thomas](https://static.independent.co.uk/static-assets/support-us/louise-thomas.png)
Louise Thomas
Editor
As governments around the world race to vaccinate their populations, scientists in Japan are exploring innovative ways of using existing medicines to treat Covid-19 patients.
In a breakthrough study, a team of Japanese scientists from leading universities and research institutions have discovered an anti-malarial drug, mefloquine — a derivative of hydrochloroquine — as an effective cure against SARS-CoV-2 - a novel severe acute respiratory syndrome coronavirus.
The scientists also mathematically modelled the effectiveness of mefloquine to predict its potential use if applied to treat Covid-19. They calculated that mefloquine could reduce the overall viral load in affected patients to under seven per cent and shorten the time taken to eliminate the virus to 6.1 days.
This study is expected to undergo clinical trials.
Some approved drugs, such as hydroxychloroquine, lopinavir, and interferon, have already been put to clinical use against SARS-CoV-2 without establishing their clinical efficacy.
Only remdesivir, which was developed to treat Hepatitis C, has been approved for clinical use against severe Covid-19, although its effectiveness is still being challenged.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments